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Abstract
Background: Determining the trend and severity of withdrawal symptoms is considered as the first stage of addiction treatment.
Objectives: Therefore, The purpose of this study was to investigate the trend and severity of withdrawal symptoms in metham-
phetamine (meth) addicts.
Patients and Methods: This cross-sectional study was conducted on all the clients admitted to quit methamphetamine abuse in a
residential treatment center for homeless addicts in Alborz province. According to the average daily intake, the clients were divided
into two groups: mild and severe. To collect the data for this study; methamphetamine withdrawal symptoms assessment scale,
Beck Depression Inventory (BDI) and a demographic information questionnaire were used. The analysis of variance (ANOVA) was
done for repeated measures through the SPSS software version 16 and at a significance level of 0.05.
Results: The findings showed that methamphetamine withdrawal symptoms including anxiety, abuse craving, and fatigue in the
first 24 hours and the first, the second, and the third weeks as well as the symptoms of depression within three weeks after the
withdrawal began to decline significantly (P < 0.0001). Following the analysis of variance (ANOVA) for repeated data and taking
addiction severity index into account, it was observed that the difference between the two groups of mild and severe addicts was
significant in terms of the trend and severity of methamphetamine withdrawal symptoms (P < 0.0001).
Conclusions: The hardest stage to quit methamphetamine addiction was the first 24 hours after withdrawal with a downward
trend; however, abuse craving especially in severe addicted group persisted even after the third week of withdrawal which could be
a risk factor for recurrence and re-abuse. Thus, it was suggested that therapists were required to pay more attention to this issue in
the treatment of this group of addicted individuals.
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1. Background
The abuse of illicit and psychoactive drugs has turned
into a common problem in today’s world (1). In this re-
spect, the global prevalence of methamphetamine abuse
is 0.4% and it is ranked in the second place among these
drugs (2). According to the office for combating drugs and
crimes in the United Nations; only in 2008, the produc-
tion of methamphetamine stimulants has been 168 to 588
tons (3). The report released by this office in 2014 also in-
dicated that the abuse of methamphetamine compounds
was as a growing global epidemic. According to this report,
the number of laboratories producing methamphetamine
compounds has increased from 12567 cases in 2011 to 14322
cases in 2012. This report has also introduced Iran among
the nations with an upward trend of drug abuse and pro-
duction of amphetamine compounds in a way that discov-
ery of illicit ephedrine used to produce such substances
in Iran has grown from 2378 kg in 2010 to 3809 kg in
2011 (4). Today’s challenge to Iran is the changing pat-
terns of drug abuse from traditional to industrial sub-
stances. This phenomenon demands a new reaction of
its kind because industrial substances, unlike traditional
ones, are not imported from specific geographic bound-
aries but they can be produced in small laboratories even
in homes (5). According to the latest statistics and the re-
sults of the rapid situation assessment (RSA) of drug abuse
in Iran, the frequency of Iranian methamphetamine ad-
dicts was reported by 5.3% out of the total number of drug
abusers (6). Moreover, the prevalence of the abuse of this
substance based on other studies was about 18.5% in the
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youth aged 15 to 25 years in Tehran (7), 4.3% among uni-
versity students in the cities of Birjand and Gilan (8, 9),
and 0.18% in college students in Hamadan (10). There are
several reasons for the increase methamphetamine abuse
such as rising costs of traditional opioids, lower price of
industrial stimulants, and easy access to these substances
(11, 12). Research studies have also revealed that the abuse
of this illicit drug can lead to specific behavior patterns
such as depression, sleep disorders, seizures, and aggres-
sive behaviors (13). As Brechet et al. argued, 50% of pa-
tients who stopped methamphetamine abuse experienced
recurrence and came back to the cycle of addiction to this
drug. This recurrence took place in 36% of cases during the
first 6 months after withdrawal (14). Other research stud-
ies have highlighted physiological dependence and abuse
craving as two important factors affecting relapse and re-
turn to the cycle of addiction among recovered individuals
(15-17). Despite the widespread and illicit use of metham-
phetamine compounds as well as the problems associated
with them, only a few patients have asked for help from
medical centers up until now. Reluctance to receive treat-
ment could be due to the belief that treatment centers and
their programs have been just for opioid-like substance
abusers and they have given no help in terms of changes
and treatments in their abuse manner (18, 19). Deficien-
cies in the management of withdrawal symptoms during
treatment may cause a lot people abandon treatment on
the first few days or weeks after withdrawal (14). A better
understanding of the natural process and the symptoms
of methamphetamine withdrawal can help in preventing
its recurrence (20, 21). Therefore, the first important stage
in an effective treatment is to determine the duration and
severity of withdrawal symptoms. Checking this informa-
tion will also facilitate the timely implementation of ap-
propriate interventions (22).
2. Objectives
Given the mentioned issues and considering that there
have been limited studies in terms of the natural process
of methamphetamine abuse in Iran to date, the purpose of
this study was to determine the trend and severity of with-
drawal symptoms in methamphetamine-addicted clients
in a residential treatment center for homeless addicts in
Alborz province in 2014.
3. Patients and Methods
This cross-sectional study was conducted in a resi-
dential treatment center for homeless addicts in Alborz
province. The statistical population of this study included
all patients over 15 years old with observed metham-
phetamine in their urine detected by rapid diagnostic kits
during the study period and at the moment of admission
to the center as well as meeting diagnostic criteria (DSM-IV)
for addiction to methamphetamine compounds and ad-
dicted only to this substance (N = 100). The clients with psy-
chosis or serious medical illnesses, individuals in need of
psychotherapy, or those addicted to drugs other than nico-
tine were excluded from this study. Based on the average
daily intake (in grams), the clients were divided into two
groups: mild (with a consumption level below the average)
and severe (with an intake level higher than the average)
(23).
3.1. Data Collection Instrument
Three questionnaires were used to collect the data: 1, a
demographic questionnaire which included patients’ gen-
eral information such as age, gender, level of education,
etc.; 2, Persian version of amphetamine cessation symp-
tom assessment (ACSA) questionnaire. The original ver-
sion of this questionnaire is designed by McGregor et al.
(24). This questionnaire developed with 16 items to as-
sess symptoms such as abuse craving, fatigue, restless-
ness, lack of a sense of joy, confusion, anxiety, sleepless-
ness, nightmare, and slow movements in which the items
were rated based on a Likert-type scale ranging from 1 (not
at all) to 5 (very high). The total score for this question-
naire was between 16 and 80 and higher scores meant more
severity of withdrawal symptoms. Moreover, this question-
naire was composed of three dimensions of anxiety and
mood, fatigue, and abuse carving. A Persian-version of
the ACSA questionnaire was translated from English and
proofed using the backward-forward translation method
(25). To explore the face validity of the questionnaire, 10
experts provided direction for the writing, translating and
arrangement of questions. A group discussion was facil-
itated through individual sessions where amphetamine
withdrawal symptoms were discussed and the question-
naire was provided before administration, content validity
index (CVI), factor analysis and principal component anal-
ysis were used to assess construct validity and validation
the Persian version of questionnaire (26). For this purpose
questionnaire was reviewed and confirmed by researchers
and professors working in this field. Cronbach’s alpha
was used to assess the internal reliability of the question-
naire. That reliability of the questionnaire was also equal
to 84%. This questionnaire was completed 24 hours after
withdrawal on a daily basis for 21 days; and 3. Beck depres-
sion inventory which has been commonly used in various
studies. It was a 21-item questionnaire with four-choice an-
swers rated from 0 to 3 on a Likert-type scale. Accordingly, it
divided individuals into five groups of without depression,
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mild depression, moderate depression, severe depression,
and very severe depression. This inventory was completed
during the first, the second, and the third weeks of treat-
ment.
To conduct this study, necessary coordination was
made with officials from a residential treatment center for
homeless addicts in Alborz province. Likewise; after the
explanation of the objectives of the study, an informed
consent form was completed by participants. To adminis-
ter the questionnaires, two trained investigators were re-
cruited and took part in a training session on how to com-
plete them. The SPSS software version 16 was also used
to analyze the data. Demographic information and data
on the amount and duration of abuse among individuals
were investigated using descriptive methods. Then, the
means and standard deviations for the first day, the sev-
enth day, the fourteenth day, and the twenty-first day were
calculated separately for groups. To examine the changes
in the means of the severity of symptoms over three weeks
as well as the differences in the severity of symptoms in
groups, analysis of variance (ANOVA) for repeated data at
a significance level of 0.05 was used.
4. Results
The average daily intake of methamphetamine in pa-
tients was 1.675 grams. According to this indicator, these
addicts were divided into two groups: severe addicts (tak-
ing over 1.675 grams per day) and mild ones (less than 1.675
grams per day). All the participants in the study were male
and smokers. The demographic characteristics of the par-
ticipants in this study are presented in Table 1.
The results of this study showed that metham-
phetamine withdrawal symptoms including anxiety,
abuse craving, and fatigue in both mild and severe groups
were observed in the first 24 hours, the first week, the
second week, and the third week; and depression symp-
toms began to decline significantly within three weeks
after withdrawal (P < 0.0001). By conducting analysis
of variance (ANOVA) for repeated data and considering
addiction severity index in the analysis of the results, it
was revealed that the difference between the two groups
of mild and severe addicts was statistically significant
in terms of the trend and severity of methamphetamine
withdrawal symptoms (P < 0.0001). These findings are
shown in Table 2.
5. Discussion
According to the findings of this study, the mean for
the total score of methamphetamine withdrawal symp-
toms scale among the participants on the first day of with-
drawal was the highest one and it significantly declined
within three weeks (P < 0.0001). These symptoms among
severe addicts compared at the same time to mild addicted
patients were at a higher level. The results of this study
were somewhat consistent with those found by McGregor
et al. They showed that methamphetamine withdrawal
symptoms within the first 24 hours had the highest sever-
ity and then reduced within 7 to 10 days (23). In a study con-
ducted in Iran by Bagheri et al. depression symptoms re-
duced after of withdrawal methamphetamine which was
consistent with the results of our study. However, symp-
toms related to anxiety in that study did not change and in
this respect not match by our study (27). In another similar
study conducted by Taod Zorick et al., methamphetamine
withdrawal symptoms had the highest severity within the
first 24 hours and then declined within two weeks (28). Al-
though, like other studies, methamphetamine withdrawal
symptoms within the first 24 hours had the highest sever-
ity and then reduced over time in the present study; the
decline in the severity of withdrawal symptoms took place
at a slower rate so that the decreasing trend in severe ad-
dicts over three weeks was slower than that among the
mild group and the withdrawal symptoms did not disap-
pear even after this period. This would probably indicate
that methamphetamine addicts in Iran required a longer
treatment period.
Based on the results of the present study, craving for
methamphetamine abuse during the first 24 hours after
withdrawal was at a maximum level and then decreased
gradually. Craving for methamphetamine had the highest
severity on the first day of withdrawal and declined at the
end of the second week; however, it did not fade away and
temptation to methamphetamine abuse was observed at
the fifth week following withdrawal. Craving for metham-
phetamine is a very important factor to quit this substance.
That is, high craving rate for methamphetamine increases
the likelihood of recurrence for this substance (29). So, as
it was shown in a prospective study, craving rate of over
20% (on a scale of one hundred points) increased the rel-
ative risk of methamphetamine relapse up to two times
(30). Thus, continued craving after methamphetamine
withdrawal could be a risk factor for recurrence and re-
abuse. Since the results of this study showed that craving
for methamphetamine especially in the severe group of ad-
dicts lasted even three weeks after withdrawal, the thera-
pists of this group of addicts were required to pay more at-
tention to this issue.
The issue of sleep, which was assessed in this study only
by one item in the fatigue factor, has been investigated
in some studies with a separate multiple-choice question-
naire considering several different dimensions such as du-
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Table 1. Demographic Characteristics of the Participants in This Study
Variables Mild Addicts Severe Addicts Statistic P Value
Age, mean (SD) 27.50 (6.538) 32.60 (5.443) T = 3.75 < 0.0001
Level of education, No. (%) X2 = 4.76 < 0.029
Below diploma 52 (74.3) 28 (93.3)
Diploma and higher 18 (25.7) 2 (6.7)
Employment status, No. (%) X2 = 28 < 0.004
Employed 33 (47.1) 5 (16.7)
Unemployed 37 (52.9) 25 (83.3)
Marital status, No. (%) X2 = 13.15 < 0.001
Single 17 (24.3) 1 (3.3)
Married 26 (37.1) 6 (20)
Divorced 28 (38.6) 23 (76.7)
ration of sleep, sleep continuity, sleep per night, daytime
sleep, quality of sleep, depth of sleep, and satisfaction with
sleep (23, 31). The results of this study were consistent with
the findings by McGregor et al. (23) and Rawson et al. (31).
In terms of duration of sleep. They found that drowsiness
and sleep duration in these patients reduced over time and
there was a significantly downward trend at the end of the
twenty-first day. In these two studies; other dimensions of
sleep including quality of sleep and depth of sleep were
also investigated and it was found that although sleepiness
and sleep duration in these patients became normal over
time; the quality and depth of sleep among these patients
was low even after three weeks, they slept late at night, and
woke up more during sleep. However, these issues were
not investigated in the present study. The results of this
study were not in line with an investigation by Gosop et al.
in which they found that the number of hours of sleep per
night in methamphetamine abusers on the first 20 days af-
ter the withdrawal was significantly lower compared with
that in the control group (20).
Beck depression inventory with 21 items was also used
to review the natural process of depression symptoms
among individuals quitting methamphetamine in this
study. This questionnaire was completed on a weekly ba-
sis for three weeks by participants in the study. The re-
sults showed that the severity of depression symptoms
significantly decreased in both groups after three weeks.
Although there was a significant difference between the
means of these two groups (P < 0.001), depression symp-
toms were observed in severe addicted group even after
the third week of withdrawal. This study was in agreement
with the findings of McGregor et al. as well as Zordick
et al. (23, 28). In which the severity of depression symp-
toms in these patients declined over time. The main point
to mention was that depression symptoms in their stud-
ies disappeared within 7 to 14 days, but it took more than
three weeks in the present study to eliminate the symp-
toms of depression completely especially in severe addicts.
These findings were consistent with the results of previous
studies in which long-term depression occurred after with-
drawal from methamphetamine (31, 32). Studies have also
shown that methamphetamine-addicted patients were at
higher risks for depression and suicide attempts (33). On
the other hand, depression symptoms might not fully dis-
appear due to short-term treatment period (34). Given that
the symptoms of depression in this study persisted for a
long time, it seemed that increasing the length of treat-
ment particularly in terms of the relief of depression symp-
toms was helpful to this group of patients.
5.1. Limitations and Suggestions
All the participants in this study were male. Therefore
it was recommended to conduct further studies on individ-
uals inclined to quit drug abuse as well as female addicts
in order to determine the trend and severity of metham-
phetamine withdrawal symptoms better. The results of
this study demonstrated that withdrawal symptoms par-
ticularly depression and abuse craving persisted for over
three weeks; thus, it was suggested to check depression
and abuse craving as withdrawal symptoms in a long-term
period. The variable of sleep was also assessed in this study
only in one item in methamphetamine withdrawal symp-
toms assessment scale and it was better to study sleep sta-
tus of these patients with specific and validated scales.
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Table 2. The Trend and Severity of Methamphetamine Withdrawal Symptoms, Anxiety and Mood, Abuse Craving, Fatigue, and Depression Using Analysis of Variance (ANOVA)
for Repeated Dataa
























Mild addicts 76.62 (0.66) 69.68 (3.21) 55.75 (4.74) 20.54 (1.53) P < 0.001
Severe
addicts
75.86 (0.34) 71.13 (2.64) 65.40 (3.38) 48.40 (1.16) P < 0.001








Mild addicts 54.75 (0.50) 49.14 (2.53) 37.95 (4.32) 11.42 (1.01) P < 0.001
Severe
addicts








Mild addicts 10 (0.000) 8.88 (0.57) 6.95 (0.78) 2.05 (0.37) P < 0.001
Severe
addicts









Mild addicts 10.88 (0.32) 11.65 (0.86) 10.84 (0.92) 7.05 (0.58) P < 0.001
Severe
addicts





Mild addicts - 68.32 (6.80) 47.78 (6.40) 24.81 (2.48) P < 0.001
Severe
addicts
- 79.13 (1.88) 70.70 (3.27) 51.16 (0.87) P < 0.001
aValues are expressed as mean (SD).
5.2. Conclusion
Since the hardest stage in methamphetamine with-
drawal was the first days of withdrawal particularly the
first 24 hours according to the results of this study, it was
necessary for addiction therapist to consider this issue in
preventing the recurrence of abuse. Moreover, the results
of this study revealed that withdrawal symptoms reduced
over time but abuse craving for methamphetamine partic-
ularly in the severe addicted group persisted even within
three weeks after they cut it off. It was concluded that
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if therapist do not pay attention to this issue, it can be
an important risk factor affecting the recurrence of abuse
among the recovered individuals.
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